UK markets closed

Merck & Co., Inc. (MRK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
127.15-1.04 (-0.81%)
At close: 04:01PM EST
128.38 +1.23 (+0.97%)
After hours: 05:48PM EST

Merck & Co., Inc.

126 East Lincoln Avenue
Rahway, NJ 07065
United States
908 740 4000
https://www.merck.com

Sector(s)Healthcare
IndustryDrug Manufacturers - General
Full-time employees70,000

Key executives

NameTitlePayExercisedYear born
Mr. Robert M. Davis J.D.Chairman, President & CEO6.08M6.77M1967
Ms. Caroline LitchfieldExecutive VP & CFO2.8MN/A1969
Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories3.44MN/A1962
Gideon BlumenthalVice President of Oncology Global Regulatory AffairsN/AN/AN/A
Dr. Joerg KoglinVice President of Global Clinical DevelopmentN/AN/AN/A
Dr. Gregory LubinieckiVP of Late-Stage Oncology DevelopmentN/AN/AN/A
Dr. Scot EbbinghausVP of Late-Stage Oncology DevelopmentN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Corporate governance

Merck & Co., Inc.’s ISS governance QualityScore as of 28 February 2024 is 4. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.